MX2010010060A - Inhibidores de ns5b de virus de la hepatitis c de indolobenzadiazepina fusionados, heterociclicos y aromaticos. - Google Patents

Inhibidores de ns5b de virus de la hepatitis c de indolobenzadiazepina fusionados, heterociclicos y aromaticos.

Info

Publication number
MX2010010060A
MX2010010060A MX2010010060A MX2010010060A MX2010010060A MX 2010010060 A MX2010010060 A MX 2010010060A MX 2010010060 A MX2010010060 A MX 2010010060A MX 2010010060 A MX2010010060 A MX 2010010060A MX 2010010060 A MX2010010060 A MX 2010010060A
Authority
MX
Mexico
Prior art keywords
indolobenzadiazepine
aromatic heterocyclic
hcv ns5b
heterocyclic fused
ns5b inhibitors
Prior art date
Application number
MX2010010060A
Other languages
English (en)
Inventor
John F Kadow
Zhong Yang
John A Bender
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2010010060A publication Critical patent/MX2010010060A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invención proporciona compuestos de la fórmula (I) (ver fórmula (I)) incluyendo sus sales, así como composiciones y métodos para usar los compuestos. Los compuestos tienen actividad contra virus de la hepatitis C (HCV) y pueden ser útiles para tratar a aquellos infectados con HCV.
MX2010010060A 2008-03-27 2009-03-24 Inhibidores de ns5b de virus de la hepatitis c de indolobenzadiazepina fusionados, heterociclicos y aromaticos. MX2010010060A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3996108P 2008-03-27 2008-03-27
PCT/US2009/038010 WO2009120650A1 (en) 2008-03-27 2009-03-24 Aromatic heterocyclic fused indolobenzadiazepine hcv ns5b inhibitors

Publications (1)

Publication Number Publication Date
MX2010010060A true MX2010010060A (es) 2010-09-30

Family

ID=40810527

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010010060A MX2010010060A (es) 2008-03-27 2009-03-24 Inhibidores de ns5b de virus de la hepatitis c de indolobenzadiazepina fusionados, heterociclicos y aromaticos.

Country Status (10)

Country Link
US (1) US8431568B2 (es)
EP (1) EP2278977B1 (es)
JP (1) JP2011517673A (es)
KR (1) KR20100124848A (es)
CN (1) CN101980711B (es)
AT (1) ATE531373T1 (es)
AU (1) AU2009228451A1 (es)
ES (1) ES2374870T3 (es)
MX (1) MX2010010060A (es)
WO (1) WO2009120650A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103288828A (zh) * 2012-02-24 2013-09-11 中国科学院大连化学物理研究所 一种合成手性二氢-6H-吲哚并[2,1-c][1,4]-苯并二氮杂卓的方法
CN103539723A (zh) * 2013-10-29 2014-01-29 南方医科大学 一种3-氨基-2-芳甲酰基-1h-吲哚类衍生物的合成方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897392A (en) * 1989-07-03 1990-01-30 Hoechst-Roussel Pharmaceuticals, Inc. 4H-indolo(1,2-d)(1,2,4)triazolo(4,3-A)(1,4)benzodiazepines
JP4143669B2 (ja) 2004-02-24 2008-09-03 日本たばこ産業株式会社 ４環縮合複素環化合物及びそのｈｃｖポリメラーゼ阻害剤としての利用
US7153848B2 (en) * 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7348425B2 (en) 2004-08-09 2008-03-25 Bristol-Myers Squibb Company Inhibitors of HCV replication
EP1807397A2 (en) 2004-10-26 2007-07-18 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Tetracyclic indole derivatives as antiviral agents
GB0518390D0 (en) 2005-09-09 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US7399758B2 (en) 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7473688B2 (en) 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
US7456165B2 (en) 2006-02-08 2008-11-25 Bristol-Myers Squibb Company HCV NS5B inhibitors
GB0608928D0 (en) * 2006-05-08 2006-06-14 Angeletti P Ist Richerche Bio Therapeutic agents
WO2007140200A2 (en) 2006-05-25 2007-12-06 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
CN101490054B (zh) 2006-05-25 2012-05-16 百时美施贵宝公司 环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂
US7452876B2 (en) 2006-06-08 2008-11-18 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
KR20090029827A (ko) * 2006-07-20 2009-03-23 제네랩스 테크놀로지스, 인코포레이티드 폴리사이클릭 바이러스 억제제
US7642251B2 (en) 2007-08-09 2010-01-05 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8143243B2 (en) 2007-08-09 2012-03-27 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7652004B2 (en) 2007-08-09 2010-01-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
WO2009120890A1 (en) 2008-03-27 2009-10-01 Bristol-Myers Squibb Company Dioxolane and dioxolanone fused indolobenzadiazepine hcv ns5b inhibitors
US8133884B2 (en) 2008-05-06 2012-03-13 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C

Also Published As

Publication number Publication date
ES2374870T3 (es) 2012-02-22
ATE531373T1 (de) 2011-11-15
CN101980711B (zh) 2012-10-31
JP2011517673A (ja) 2011-06-16
EP2278977B1 (en) 2011-11-02
AU2009228451A1 (en) 2009-10-01
KR20100124848A (ko) 2010-11-29
US20110014154A1 (en) 2011-01-20
US8431568B2 (en) 2013-04-30
CN101980711A (zh) 2011-02-23
WO2009120650A1 (en) 2009-10-01
EP2278977A1 (en) 2011-02-02

Similar Documents

Publication Publication Date Title
TW200745120A (en) Indolobenzazepine HCV NS5B inhibitors
WO2010030538A3 (en) Compounds for the treatment of hepatitis c
MX2012004032A (es) Compuestos para el tratamiento de hepatitis c.
PL1987038T3 (pl) Inhibitory HCV NS5B
ATE469155T1 (de) Cyclopropyl-fusionierte indolbenzazepin-hcv-ns5b- hemmer
PL2209789T3 (pl) Skondensowane z cyklopropylem indolobenzoazepinowe inhibitory NS5B HCV
TW200745035A (en) Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
MX2009009473A (es) Compuestos para el tratamiento de hepatitis c.
MX2010008699A (es) Derivados heterociclicos como inhibidores de virus de la hepatitis c.
WO2007140200A3 (en) Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
EA201100390A1 (ru) Соединения для лечения гепатита с
MY152070A (en) Macrocyclic quinxaline compounds as hcv ns3 protease inhibitors
MX2012008443A (es) Nucleosidos antiviricos.
MX2012003170A (es) Compuestos heterociclicos antivirales.
MX2010008531A (es) Derivados de bifenilo conformacionalmente restringido para uso como inhibidores del virus de la hepatitis c.
MX2010004623A (es) Compuestos heterociclicos antiviricos.
MX2013002927A (es) Inhibidores del virus de la hepatitis c.
MX2010001416A (es) Compuesto para el tratamiento de la hepatitis c.
ATE522532T1 (de) Verbindungen zur behandlung von hepatitis c
CO6400218A2 (es) Compuestos heterocíclicos antivirales
ATE494291T1 (de) Verbindungen zur behandlung von hepatitis c
ATE551343T1 (de) Tetracyclische verbindungen zur behandlung von hepatitis c
ATE505473T1 (de) Cyclopropylkondensierte indolobenzazepinderivate zur behandlung von hepatitis c
MX2011012541A (es) Compuestos heterociclicos antivirales.
MX2010010061A (es) Compuestos para el tratamiento de hepatitis c.

Legal Events

Date Code Title Description
FG Grant or registration